Navigation Links
FDA Grants NeoVista's Request to Utilize Novel Wet AMD Treatment in Compassionate Case
Date:12/10/2008

NeoVista's Epiretinal Brachytherapy Granted Compassionate Use to Attempt to Prevent Complete Vision Loss in Patient

FREMONT, Calif., Dec. 10 /PRNewswire/ --NeoVista, Inc., announced today that the U.S. Food and Drug Administration (FDA) had approved the company's "compassionate case" waiver to utilize its novel wet age-related macular degeneration (AMD) treatment on a patient with an advanced form of the disease who did not meet criteria for inclusion into current NeoVista investigational treatment protocols. The patient received NeoVista's therapy today in Nashville, Tenn.; the procedure was performed by Dr. Carl Awh, President of Tennessee Retina, and an investigator in NeoVista's ongoing Phase III study, CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy).

The patient suffered from advanced wet AMD in both eyes and had not benefited from any available treatment, including anti­vascular endothelial growth factor (anti-VEGF) agents, the current standard of care for wet AMD. The patient's left eye had progressively worsened despite treatment with photodynamic therapy and intravitreal steroids prior to the advent of anti-VEFG therapy, as well as later injections of anti-VEGF agents. Her right eye was following a parallel course, with advanced vision loss due to an enlarging exudative retinal detachment caused by wet AMD. Because of the similarity in the appearance of the two eyes and the failure of prior therapies to successfully treat the left eye, a decision was made to treat the patient's right eye with NeoVista's therapy.

"With the FDA granting a waiver for this case, today both my patient and I had access to a promising, new therapy for the treatment of her case of severe wet AMD," said Dr. Awh. "If this approach proves effective in her case, other patients with similar types of advanced, progressive wet AMD may also benefit under compassionate use waivers from the FDA."

NeoVista's novel therapy applies a targeted dose of beta radiation to the abnormal leaking blood vessels that affect central vision in patients with wet AMD. Preliminary data show that NeoVista's targeted radiation therapy can be safe for both the patient and the physician, and may be able to improve patient's vision. The current standard of care for wet AMD requires monthly injections of anti-VEGF drugs into the eye for an indefinite period of time.

In contrast to other forms of radiation therapy for wet AMD, NeoVista's approach delivers the peak dose of energy directly to the lesion without damaging the normal retinal vasculature. Utilizing strontium 90, the focused energy is delivered to a target area up to 3 mm in depth and up to 5.4 mm in diameter. Importantly for patients, the systemic exposure to radiation is minimal, as the effective dose to the entire body from NeoVista's epiretinal device is less than that from a typical chest x-ray.

"We're extremely pleased that the FDA has granted us a compassionate use waiver in this circumstance," said John N. Hendrick, President and CEO of NeoVista. "Even though this patient has not benefited from currently approved therapies, our hope is that she will benefit from our treatment as a final effort to avoid complete loss of vision."

The purpose of the compassionate use waiver is to offer a limited number of patients with serious conditions and no other alternatives the opportunity to potentially benefit from an investigational treatment that has not yet been approved for use by the FDA. While receiving the compassionate use approval for this patient, NeoVista continues to enroll patients in the company's pivotal trial, CABERNET.

CABERNET is a multicenter, randomized, controlled study that will enroll 450 subjects at 45 sites worldwide, evaluating the safety and efficacy of NeoVista's epiretinal brachytherapy delivered concomitantly with the FDA-approved anti-VEGF therapy Lucentis(R) (ranibizumab) versus Lucentis alone.

About NeoVista, Inc.

NeoVista, Inc. is a privately held development-stage medical device company based in Fremont, California. NeoVista's epiretinal beta radiation therapy is currently being studied in a definitive Phase III clinical study to support eventual filing for regulatory approval to market the product in the United States. For more information about the company, the clinical trial or this novel wet AMD therapy, please visit the company's Web site at www.neovistainc.com. For detailed information about the CABERNET clinical trial, please visit the study Web site at www.cabernetstudy.com.

    Contact:  Tony Moses
          O:  510.933.7600
          C:  510.402.3394
          tmoses@neovistainc.com


'/>"/>
SOURCE NeoVista, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Labor Department Awards $10.1 Million for Safety and Health Training Grants
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide
4. USAID Announces First Malaria Communities Program Grants
5. The Highmark Foundation Awards $580,000 in Highmark Healthy High 5 Grants to Four Non-Profit Organizations
6. KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants
7. FDA Grants Clearance to Langford IC Systems, Inc.
8. Dienst Custom Homes Grants Over 40 Wishes in Three Years
9. United Animal Nations Offers Financial Assistance Grants of up to $500 to Help Southern California Fire Victims Obtain Vet Care, Temporary Boarding for Pets
10. PA Health Department Awards Community Primary Care Challenge Grants
11. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers of the wildly popular ... bodybuilder Breon Ansley to its growing team of brand ambassadors. The Olympia top finisher ... in less than a year was able to turn professional, participating in the 2013 ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities ... These resources have been developed for use by nutrition educators and influencers ...
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated ... met with big-name retail buyers at the January ECRM Trade Show in Hilton Head, ... the utmost safety standards in all of its creations to help create a more ...
(Date:1/21/2017)... ... January 21, 2017 , ... "ProDOF is the perfect set of tools for video ... subject in a scene," said Christina Austin - CEO of Pixel Film Studios. , ... Easily create the illusion of a DSLR racking focus from one area into the next. ...
(Date:1/21/2017)... ... 21, 2017 , ... Santa Rosa Orthopaedics (SRO) is excited ... 167 Lynch Creek Way. The Petaluma office features three comfortable patient exam rooms, ... services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. Neema Pourtaheri ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 Longer life expectancy and rising healthcare expenditure ... for medical device technologies. BCC Research reveals in its new ... region, should see strong growth due to rising government healthcare ... Continue Reading ... ...
(Date:1/23/2017)... -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: ... agreement with the Children,s Hospital of Philadelphia ... US key opinion leader in the mitochondrial medicine field. ... Dr. ... research program, NVP015, in certain experimental disease models. The research ...
(Date:1/21/2017)... -- ResMed (NYSE: RMD ), BMC ( Beijing, ... ) today announced they have agreed on a global settlement ... permitted to sell their existing products in exchange for royalty payments ... 3B to close the Florida litigation between ... liability or wrongdoing by any party. The five-year ...
Breaking Medicine Technology: